Local Recurrence After Breast-Conserving Surgery and Mastectomy Following Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer - a Meta-Analysis

Overview

Journal Breast Care (Basel)

Publisher Karger

Date 2016 Dec 7

PMID 27920628

Citations 16

Authors

Xiaodong Zhou

Yujie Li

Affiliations

Soon will be listed here.

Abstract

Background: Breast-conserving surgery (BCS) in patients with large tumors shrunk by neoadjuvant chemotherapy (NCT) remains controversial. We conducted a meta-analysis to evaluate the local recurrence rates in locally advanced breast cancer (LABC) patients receiving NCT comparing BCS with mastectomy.

Methods: Pubmed, Web of Knowledge, and Ovid's database were searched for studies concerning treatment for LABC from January 2000 to June 2015. A meta-analysis was performed to compare the recurrence rates of patients receiving BCS versus mastectomy following NCT.

Results: 8 trials with a total of 3,215 patients were analyzed. The prevalence of local recurrence was 9.2% in the BCS group versus 8.3% in the mastectomy group without significant difference (odds ratio (OR) 1.07, 95% confidence interval (CI) 0.28-1.48; p = 0.66). The 5-year local recurrence-free survival (LRFS) rate was lower in the mastectomy group than in the BCS group, but no significant difference was found between the 2 groups (OR 1.11, 95% CI 0.61-1.99; p = 0.74).

Conclusion: BCS after NCT is safe in terms of local recurrence and LRFS in LABC women. Shrinking tumors with NCT provides the opportunity to apply BCS with no detriment to outcome.

Citing Articles

Machine learning prediction of breast cancer local recurrence localization, and distant metastasis after local recurrences.

Kovacs K, Kerepesi C, Rapcsak D, Madaras L, Nagy A, Takacs A Sci Rep. 2025; 15(1):4868.

PMID: 39929942 PMC: 11811162. DOI: 10.1038/s41598-025-89339-9.

Prognosis of patients with breast cancer who underwent breast-conserving surgery using a 3D-printed surgical guide after neoadjuvant chemotherapy.

Kim A, Lee S, Yoo T, Kim J, Chung I, Kim H Sci Rep. 2025; 15(1):86.

PMID: 39747396 PMC: 11696551. DOI: 10.1038/s41598-024-82968-6.

Survival Outcomes of Breast-Conserving Surgery Versus Mastectomy in Locally Advanced Breast Cancer Following Neoadjuvant Chemotherapy: A Meta-Analysis.

Qin R, Yin L, Wang D, Cao X, Shaibu Z, Wang X Technol Cancer Res Treat. 2024; 23:15330338241265030.

PMID: 39043051 PMC: 11271104. DOI: 10.1177/15330338241265030.

The Role of Human Epidermal Growth Factor Receptor 2 (HER2)-Targeted Therapies in Early-Stage Breast Cancer: Current Practices, Treatment De-escalation, and Future Prospects.

Hashem M, Rehman S, Salhab M Cureus. 2024; 16(2):e55230.

PMID: 38558735 PMC: 10981386. DOI: 10.7759/cureus.55230.

The Current Role of Neoadjuvant Chemotherapy in the Management of HER2-Positive, Triple-Negative, and Micropapillary Breast Cancer: A Narrative Review.

Wankhade D, Gharde P, Dutta S Cureus. 2024; 15(11):e49742.

PMID: 38161817 PMC: 10757756. DOI: 10.7759/cureus.49742.

References

Touboul E, Lefranc J, Blondon J, Buffat L, Deniaud E, Belkacemi Y . Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced non-inflammatory breast cancer. Radiother Oncol. 1997; 42(3):219-29. DOI: 10.1016/s0167-8140(97)01923-3. View

Singletary S, McNeese M, Hortobagyi G . Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer. 1992; 69(11):2849-52. DOI: 10.1002/1097-0142(19920601)69:11<2849::aid-cncr2820691134>3.0.co;2-p. View

van der Hage J, van de Velde C, Julien J, Tubiana-Hulin M, Vandervelden C, Duchateau L . Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001; 19(22):4224-37. DOI: 10.1200/JCO.2001.19.22.4224. View

Cance W, Carey L, Calvo B, Sartor C, Sawyer L, Moore D . Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg. 2002; 236(3):295-302; discussion 302-3. PMC: 1422583. DOI: 10.1097/01.SLA.0000027526.67560.64. View

Chen A, Meric-Bernstam F, Hunt K, Thames H, Oswald M, Outlaw E . Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004; 22(12):2303-12. DOI: 10.1200/JCO.2004.09.062. View

Barranger E, Antomarchi J, Chamorey E, Cavrot C, Flipo B, Follana P . Effect of Neoadjuvant Chemotherapy on the Surgical Treatment of Patients With Locally Advanced Breast Cancer Requiring Initial Mastectomy. Clin Breast Cancer. 2015; 15(5):e231-5. DOI: 10.1016/j.clbc.2015.03.001. View

Cho J, Park J, Park H, Park S, Kim S, Park B . Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer. J Surg Oncol. 2013; 108(8):531-6. DOI: 10.1002/jso.23439. View

Huang E, Tucker S, Strom E, McNeese M, Kuerer H, Buzdar A . Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004; 22(23):4691-9. DOI: 10.1200/JCO.2004.11.129. View

Debled M, MacGrogan G, Breton-Callu C, Ferron S, Hurtevent G, Fournier M . Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude. Eur J Cancer. 2015; 51(6):697-704. DOI: 10.1016/j.ejca.2015.01.063. View

10.

Rouzier R, Pusztai L, Garbay J, Delaloge S, Hunt K, Hortobagyi G . Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer. 2006; 107(7):1459-66. DOI: 10.1002/cncr.22177. View

11.

Rouzier R, Mathieu M, Sideris L, Youmsi E, Rajan R, Garbay J . Breast-conserving surgery after neoadjuvant anthracycline-based chemotherapy for large breast tumors. Cancer. 2004; 101(5):918-25. DOI: 10.1002/cncr.20491. View

12.

Shin H, Han W, Moon H, Im S, Moon W, Park I . Breast-conserving surgery after tumor downstaging by neoadjuvant chemotherapy is oncologically safe for stage III breast cancer patients. Ann Surg Oncol. 2013; 20(8):2582-9. DOI: 10.1245/s10434-013-2909-6. View

13.

Ishitobi M, Ohsumi S, Inaji H, Ohno S, Shigematsu H, Akiyama F . Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson Prognostic Index. Cancer. 2012; 118(18):4385-93. DOI: 10.1002/cncr.27377. View

14.

McGuire S, Gonzalez-Angulo A, Huang E, Tucker S, Kau S, Yu T . Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007; 68(4):1004-9. PMC: 4329732. DOI: 10.1016/j.ijrobp.2007.01.023. View

15.

Kuerer H, Newman L, Smith T, Ames F, Hunt K, Dhingra K . Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17(2):460-9. DOI: 10.1200/JCO.1999.17.2.460. View

16.

Sweeting R, Klauber-DeMore N, Meyers M, Deal A, Burrows E, Drobish A . Young women with locally advanced breast cancer who achieve breast conservation after neoadjuvant chemotherapy have a low local recurrence rate. Am Surg. 2011; 77(7):850-5. PMC: 4167782. View

17.

Huang E, Strom E, Perkins G, Oh J, Chen A, Meric-Bernstam F . Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score. Int J Radiat Oncol Biol Phys. 2006; 66(2):352-7. DOI: 10.1016/j.ijrobp.2006.04.046. View

18.

Vlastos G, Mirza N, Lenert J, Hunt K, Ames F, Feig B . The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy. Cancer. 2000; 88(6):1417-24. DOI: 10.1002/(sici)1097-0142(20000315)88:6<1417::aid-cncr20>3.0.co;2-1. View

19.

Makris A, Powles T, Ashley S, Chang J, Hickish T, Tidy V . A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol. 1998; 9(11):1179-84. DOI: 10.1023/a:1008400706949. View

20.

Chawla A, Hunt K, Mittendorf E . Surgical considerations in patients receiving neoadjuvant systemic therapy. Future Oncol. 2012; 8(3):239-50. DOI: 10.2217/fon.12.12. View